Neurocrine Biosciences
Develops and commercializes neuroscience and rare-disease medicines led by INGREZZA.
$154.94
After-hours close+0.88 (+0.57%)
At close$154.06(−1.19%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $2.59 | — | — |
| Jul 2026 | $1.65 | $1.39 | −15.8% |
| May 2026 | $1.28 | $1.94 | +51.6% |
| Feb 2026 | $1.80 | $1.88 | +4.4% |
| Oct 2025 | $1.58 | $2.04 | +29.1% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Jul 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Oct 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Oct 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Jul 2019 | |||
| Apr 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Jul 2018 | |||
| Apr 2018 | |||
| Feb 2018 | |||
| Nov 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Oct 2015 | |||
| Jul 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Oct 27, 2026 | $2.59 | — | — | $1.04B | — | — |
| Jul 30, 2026 | $1.65 | $1.39 | −15.8% | $891.2M | $959.0M | +7.6% |
| May 5, 2026 | $1.28 | $1.94 | +51.6% | $768.3M | $814.5M | +6.0% |
| Feb 11, 2026 | $1.80 | $1.88 | +4.4% | $790.5M | $805.5M | +1.9% |
| Oct 28, 2025 | $1.58 | $2.04 | +29.1% | $806.8M | $794.9M | −1.5% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Jul 30, 2025 | ||||||
| May 5, 2025 | ||||||
| Feb 6, 2025 | ||||||
| Oct 30, 2024 | ||||||
| Aug 1, 2024 | ||||||
| May 1, 2024 | ||||||
| Feb 7, 2024 | ||||||
| Oct 31, 2023 | ||||||
| Aug 1, 2023 | ||||||
| May 3, 2023 | ||||||
| Feb 6, 2023 | ||||||
| Nov 1, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 4, 2022 | ||||||
| Feb 11, 2022 | ||||||
| Nov 1, 2021 | ||||||
| Aug 3, 2021 | ||||||
| May 5, 2021 | ||||||
| Feb 4, 2021 | ||||||
| Nov 9, 2020 | ||||||
| Aug 3, 2020 | ||||||
| May 6, 2020 | ||||||
| Feb 4, 2020 | ||||||
| Nov 4, 2019 | ||||||
| Jul 29, 2019 | ||||||
| Apr 29, 2019 | ||||||
| Feb 5, 2019 | ||||||
| Nov 5, 2018 | ||||||
| Jul 31, 2018 | ||||||
| Apr 30, 2018 | ||||||
| Feb 13, 2018 | ||||||
| Nov 1, 2017 | ||||||
| Aug 3, 2017 | ||||||
| May 9, 2017 | ||||||
| Feb 14, 2017 | ||||||
| Nov 2, 2016 | ||||||
| Aug 3, 2016 | ||||||
| May 5, 2016 | ||||||
| Feb 11, 2016 | ||||||
| Oct 29, 2015 | ||||||
| Jul 29, 2015 | ||||||